益肾通痹汤治疗活动性类风湿关节炎的非劣效性随机对照试验方案
主要疗效指标为治疗24周时基于临床疾病活动指数评估的应答比例,旨在验证益肾通痹汤的疗效。
要点
- 益肾通痹汤与甲氨蝶呤头对头比较,采用双盲双模拟设计。
- 主要终点为24周临床疾病活动指数应答比例。
- 疼痛视觉模拟评分大于40毫米者允许加用非甾体抗炎药。
核心结论
- 该试验旨在验证益肾通痹汤治疗活动性类风湿关节炎的疗效是否非劣效于甲氨蝶呤,结果尚未报告。
研究设计与样本
- 一组接受益肾通痹汤加甲氨蝶呤安慰剂,另一组接受甲氨蝶呤加益肾通痹汤安慰剂。
- 疼痛视觉模拟评分大于40毫米者给予非甾体抗炎药(如肠溶双氯芬酸钠,25毫克每日三次)。
- 于基线及治疗开始后4、12、24周评估临床指标和疾病活动度。
主要发现
- 原文未报告试验结果,仅描述研究方案。
- 既往临床观察和动物模型试验显示益肾通痹汤治疗类风湿关节炎有显著效果,但证据不足以推荐其使用。
关键数值与推荐
- 主要疗效结局为治疗24周时基于临床疾病活动指数评分显示有利应答的患者比例。
- 所有不良事件均将报告。
临床怎么用
- 该方案为益肾通痹汤治疗类风湿关节炎的疗效验证提供设计框架,结果待发表后指导临床决策。
局限性
- 原文未报告试验结果,无法评估疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatoid arthritis (RA) is a common chronic autoimmune disease that seriously affects the quality of life of patients because of damage to joints. Presently, RA is mainly treated with disease-modifying antirheumatic drugs (DMARDs) or biological agents; however, they offer limited efficacy in some patients. Therefore, additional therapeutic strategies need to be developed. Yishen Tongbi decoction is a traditional Chinese medicine formulation widely used to treat RA in China. However, currently, there is insufficient evidence to recommend its use for the treatment of RA. Therefore, we aim to verify the efficacy of Yishen Tongbi decoction to treat RA by a noninferiority trial, and to provide a basis for its use with a full-scale clinical trial. METHODS/DESIGN: One hundred eligible patients with RA will be randomized into two groups of 50 patients. One group will receive Yishen Tongbi decoction and placebo replacing methotrexate (MTX), while the other group will receive MTX and placebo replacing Yishen Tongbi decoction. Patient's whose visual analogue scale score for pain is greater than 40 mm will be administered nonsteroidal anti-inflammatory drugs (such as enteric-coated diclofenac sodium, 25 mg three times a day); administration of all medications will be recorded. The clinical indicators of patients and their disease activity will be assessed at baseline and at 4, 12 and 24 weeks after treatment initiation. The primary outcome of efficacy will be the proportion of patients who demonstrate a favourable response based on their Clinical Disease Activity Index score at 24 weeks after treatment. All adverse events will be reported. DISCUSSION: Traditional Chinese medicine theory and modern western medicine research have identified the efficacy of Yishen Tongbi decoction to treat RA. Previous clinical observation and efficacy trials of Yishen Tongbi decoction in animal models for the treatment of RA has demonstrated significant effect. Because of the potential benefits of Yishen Tongbi decoction in the treatment of patients with RA, we designed this double-blind, prospective, randomized controlled trial; the results and conclusions of the trail will be published after the completion of the study. TRIAL REGISTRATION: Chinese Clinical Trials Registry, ChiCTR1900024902. Registered on 3 August 2019.
引用
- Zhao L, Li M, Xu Y, et al. Evaluating the therapeutic efficacy of the Chinese herbal medicine Yishen Tongbi decoction in patients with active rheumatoid arthritis: protocol for a randomized, controlled, noninferiority trial. Trials. 2019. PMID: 31888728. doi:10.1186/s13063-019-4005-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。